Induction of G1 Phase Cell Cycle Arrest and Apoptosis in Breast Cancer MCF-7 Cells by Sulphonamide Derivative CID-6861424

Authors

  • Sumit Kumar Gautam Schools of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
  • Afreen Inam Department of Chemistry, Jamia Millia Islamia, New Delhi, India
  • Amir Azam Department of Chemistry, Jamia Millia Islamia, New Delhi, India
  • N. Mondal School of Life Sciences, Jawaharlal Nehru University, New Delhi, India

DOI:

https://doi.org/10.37591/rrjot.v9i2.1609

Abstract

Breast cancer is most frequently detected and leading cause of cancer death in women worldwide. 80% of the breast cancer are estrogen receptor positive and the presently available drugs are ineffective either due to intrinsic resistance or due to acquired resistance. Sulfonamide compounds are a class of compounds showing activities like, antibacterial, antiviral including antitumor. In the present study we have investigated the anti-cancerous activity of sulfonamide derivative CID-6861424 on breast cancer cell line, MCF-7. Our data shows inhibition of MCF-7 cell viability by CID-6861424 in a concentration and time dependent manner. 50μM was the IC50 value of CID-6861424 on MCF-7 cell. The compound downregulated cyclin D1 and CDK 4/6, induced G1 phase cell cycle arrest and apoptotic cell death. 50μM CID-6861424 upregulated ROS generation, disrupted mitochondrial membrane potential (Δψm), increased DNA damage and upregulated tumor suppressor protein, p53 in MCF-7 cells. The compound reduced phosphorylation of Akt and GSK-3β, downregulated Bcl-2 and upregulated Bax indicating apoptotic cell death. These results suggest CID-6861424 as a potential anticancer agent against breast cancer.

 

Keywords: CID-6861424; MCF-7 cell, cell cycle, double-strand DNA break, apoptosis.


Cite this Article

Sumit Kumar Gautam, Afreen Inam, Amir Azam, Neelima Mondal. Induction of G1 phase cell cycle arrest and apoptosis in breast cancer MCF-7 cells by sulphonamide derivative CID-6861424. Research & Reviews: A Journal of Toxicology. 2019; 9(2): 1–19p.


Downloads

Published

2019-07-15

Issue

Vol. 9 No. 2 (2019)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.